摘要
目的:检测急性髓性白血病患者外周血T淋巴细胞亚群的变化及CD56+细胞比例的临床意义。方法:选取确诊但未治疗的急性白血病30例为初治组;确诊并经化疗达完全缓解的急性白血病30例为复治组;健康志愿者30例为正常对照组。用流式细胞仪检测初治组、复治组及对照组人群的外周血T淋巴细胞亚群及CD56+细胞的比例,检测初治组中不同CD56+细胞组间患者血红蛋白及白蛋白水平。结果:初治组的CD3+T淋巴细胞、CD4+T淋巴细胞、CD8+T淋巴细胞、CD4+/CD8+比值较复治组及对照组均有显著性下降(P<0.05),而复治组与对照组比较差别无统计学意义(P>0.05)。初治组AML的CD56+细胞比例超过25%患者为40%(12/30),而复治组仅10%(3/30),差别具有统计学意义(P<0.05)。初治组中CD56+细胞高表达组的血红蛋白(Hb)及白蛋白(Alb)显著性低于正常表达组(P<0.05)。结论:初治组急性髓性血病患者的T淋巴细胞亚群变化明显,说明细胞免疫与白血病的发生、发展及转归有关;急性髓性白血病患者CD56高表达提示临床状况较差,生活质量低,可能与预后不良有关。
Objective：To study the changes of T lymphocyte subsets and CD56＋ cells in peripheral blood of patients with acute medloid leukemia and its clinical significance.Methods： AML patients who were confirmedly diagnosis but not yet treated as Group A（n=30）;patients AML patients who were confirmedly diagnosed and treated systematically with chemo-therapy and reach complete remission as Group B（n=30）;And 30 health people were enrolled as control group.We analyzed T lymphocyte subsets and CD56＋ cells by flow cytometry,and examined HB and Alb level in different CD56^＋ cell expression group.Results： Group A was significantly different from Group B and the control group in ratios of CD3＋T cells,CD4＋T cells,CD8＋T cells and CD4＋/CD8＋（P0.05）;There was no significant difference in them between Group B and the control group（P0.05）.Patients of Group A who having more than 25% CD56＋ cell were 40%（12/30）,while only 10%（3/30） in Group B.Patients who having higher CD56＋ cell percentage were associated with low HB and Alb.Conclusion： Change of T lymphocyte subsets were associated with progress or prognosis of acute meyloid leukemia.Higher CD56^＋ cell xepression perpahs were associated with poor prognosis.
出处
《中国卫生检验杂志》
CAS
2011年第1期154-155,158,共3页
Chinese Journal of Health Laboratory Technology
